Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10361722 | 0.77 | GPR84 (0.44) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18174042 | 0.77 | GPR84 (0.42) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2736494 | 0.76 | CES1 (0.41) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL15051172 | 0.75 | GPR84 (0.48) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL29783301 | 0.75 | GPR84 (0.48) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL9336210 | 0.73 | KDM4E (0.47) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18173998 | 0.73 | GPR84 (0.45) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL30585052 | 0.73 | GPR84 (0.45) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL215395 | 0.71 | SERPINE1 (0.39) | CES1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2736495 | 0.71 | ALDH1A1 (0.45) | RAB9AMAPTSMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2023-08-03 | — | — | US | claimed |
| EP-4186507-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2023-05-31 | — | — | EP | claimed |
| EP-3710004-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos NV (BE) | 2020-09-23 | — | — | EP | claimed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | claimed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | claimed |
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2023-08-03 | — | — | US | disclosed |
| EP-4186507-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2023-05-31 | — | — | EP | disclosed |
| WO-2015197550-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2015-12-30 | — | — | WO | disclosed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1175383-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066522-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CES1 747/4885NPC1 1677/4885RAB9A 4238/4885 |
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GPR84, GPR65, GPR88 | CES1 953/4885NPC1 635/4885RAB9A 2171/4885 |
| US-20020147336-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CES1 731/4885NPC1 1635/4885RAB9A 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.